Featured Research

from universities, journals, and other organizations

Chemists discover structure of cancer drug candidate

Date:
May 19, 2014
Source:
The Scripps Research Institute
Summary:
Chemists have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients. In the new study, scientists show that TIC10's structure differs subtly from a version published by another group last year, and that the previous structure associated with TIC10 in fact describes a molecule that lacks TIC10's anticancer activity.

A new report shows the structure of a promising anticancer compound, TIC10, differs subtly but importantly from a previously published version.
Credit: Image courtesy of The Scripps Research Institute.

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

Related Articles


The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10.

In the new study, the TSRI scientists show that TIC10's structure differs subtly from a version published by another group last year, and that the previous structure associated with TIC10 in fact describes a molecule that lacks TIC10's anticancer activity.

By contrast, the correct structure describes a molecule with potent anticancer effects in animals, representing a new family of biologically active structures that can now be explored for their possible therapeutic uses.

"This new structure should generate much interest in the cancer research community," said Kim D. Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.

Antitumor Potential

TIC10 was first described in a paper in the journal Science Translational Medicine in early 2013. The authors identified the compound, within a library of thousands of molecules maintained by the National Cancer Institute (NCI), for its ability to boost cells' production of a powerful natural antitumor protein, TRAIL. (TIC10 means TRAIL-Inducing Compound #10.)

As a small molecule, TIC10 would be easier to deliver in a therapy than the TRAIL protein itself. The paper, which drew widespread media coverage, reported that TIC10 was orally active and dramatically shrank a variety of tumors in mice, including notoriously treatment-resistant glioblastomas.

Tumors can develop resistance to TRAIL, but Janda had been studying compounds that defeat this resistance. The news about TIC10 therefore got his attention. "I thought, 'They have this molecule for upregulating TRAIL, and we have these molecules that can overcome tumor cell TRAIL resistance -- the combination could be important,'" he said.

The original publication on TIC10 included a figure showing its predicted structure. "I saw the figure and asked one of my postdocs, Jonathan Lockner, to make some," Janda said.

Although the other team had seemingly confirmed the predicted structure with a basic technique called mass spectrometry, no one had yet published a thorough characterization of the TIC10 molecule. "There were no nuclear magnetic resonance data or X-ray crystallography data, and there was definitely no procedure for the synthesis," Lockner said. "My background was chemistry, though, so I was able to find a way to synthesize it starting from simple compounds."

Surprising Inactivity

There was just one problem with Lockner's newly synthesized "TIC10." When tested, it failed to induce TRAIL expression in cells, even at high doses.

"Of course I was nervous," remembered Lockner. "As a chemist, you never want to make a mistake and give biologists the wrong material."

To try to verify they had the right material, Janda's team obtained a sample of TIC10 directly from the NCI. "When we got that sample and tested it, we saw that it had the expected TRAIL-upregulating effect," said Nicholas Jacob, a graduate student in the Janda Laboratory who, with Lockner, was a co-lead author of the new paper. "That prompted us to look more closely at the structures of these two compounds."

The two researchers spent months characterizing their own synthesized material and the NCI material, using an array of sophisticated structural analysis tools. With Assistant Professor Vladimir V. Kravchenko of the TSRI Department of Immunology and Microbial Science, Jacob also tested the two compounds' biological effects.

The team eventually concluded that the TIC10 compound from the NCI library does boost TRAIL production in cells and remains promising as the basis for anticancer therapies, but it does not have the structure that was originally published.

The Right Structure

The originally published structure has a core made of three carbon-nitrogen rings in a straight line and does not induce TRAIL activity. The correct, TRAIL-inducing structure differs subtly, with an end ring that sticks out at an angle. In chemists' parlance, the two compounds are constitutional isomers: a linear imidazolinopyrimidinone and an angular imidazolinopyrimidinone.

Ironically, Lockner found that the angular TRAIL-inducing structure was easier to synthesize than the one originally described.

Now, with the correct molecule in hand and a solid understanding of its structure and synthesis, Janda and his team are moving forward with their original plan to study TIC10 in combination with TRAIL-resistance-thwarting molecules as an anticancer therapy.

The therapeutic implications of TIC10 may even go beyond cancer. The angular core of the TRAIL-inducing molecule discovered by Janda's team turns out to be a novel type of a biologically active structure -- or "pharmacophore" -- from which chemists may now be able to build a new class of candidate drugs, possibly for a variety of ailments.

"One lesson from this has got to be: don't leave your chemists behind," said Janda.


Story Source:

The above story is based on materials provided by The Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nicholas T. Jacob, Jonathan W. Lockner, Vladimir V. Kravchenko, Kim D. Janda. Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL. Angewandte Chemie, 2014; DOI: 10.1002/ange.201402133

Cite This Page:

The Scripps Research Institute. "Chemists discover structure of cancer drug candidate." ScienceDaily. ScienceDaily, 19 May 2014. <www.sciencedaily.com/releases/2014/05/140519184505.htm>.
The Scripps Research Institute. (2014, May 19). Chemists discover structure of cancer drug candidate. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2014/05/140519184505.htm
The Scripps Research Institute. "Chemists discover structure of cancer drug candidate." ScienceDaily. www.sciencedaily.com/releases/2014/05/140519184505.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Matter & Energy News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

NASA's First 3-D Printer In Space Creates Its First Object

NASA's First 3-D Printer In Space Creates Its First Object

Newsy (Nov. 26, 2014) The International Space Station is now using a proof-of-concept 3D printer to test additive printing in a weightless, isolated environment. Video provided by Newsy
Powered by NewsLook.com
Bolivian Recycling Initiative Turns Plastic Waste Into School Furniture

Bolivian Recycling Initiative Turns Plastic Waste Into School Furniture

Reuters - Innovations Video Online (Nov. 26, 2014) Innovative recycling project in La Paz separates city waste and converts plastic garbage into school furniture made from 'plastiwood'. Tara Cleary reports. Video provided by Reuters
Powered by NewsLook.com
Blu-Ray Discs Getting Second Run As Solar Panels

Blu-Ray Discs Getting Second Run As Solar Panels

Newsy (Nov. 26, 2014) Researchers at Northwestern University are repurposing Blu-ray movies for better solar panel technology thanks to the discs' internal structures. Video provided by Newsy
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Space & Time

Matter & Energy

Computers & Math

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins